Formosa Biomedical Technology Corp. Announces Board Approval of Q1 2026 Financial Report
NQ Score
0/100
N1 Content Completeness
90
Key facts
- Formosa Biomedical Technology Corp. Announces Board Approval of Q1 2026 Financial Report
- Formosa Biomedical Technology Corp. (華安) announced that its Board of Directors approved the Q1 2026 financial report. The cumulative operating revenue was NT$1.391 million, with an operating loss of NT$50.802 million, a pre-tax net loss of NT$46.308 million, and a basic loss per share of NT$0.53. Total assets at the end of the period were NT$883.757 million.
- Source: TWSE
- Date: Fri May 08 2026 09:00:00 GMT+0900 (Japan Standard Time)
Direct answer
Formosa Biomedical Technology Corp. (華安) announced that its Board of Directors approved the Q1 2026 financial report. The cumulative operating revenue was NT$1.391 million, with an operating loss of NT$50.802 million, a pre-tax net loss of NT$46.308 million, and a basic loss per share of NT$0.53. Total assets at the end of the period were NT$883.757 million.
- Citation
- Formosa Biomedical Technology Corp. Announces Board Approval of Q1 2026 Financial Report (Fri May 08 2026 09:00:00 GMT+0900 (Japan Standard Time)), TWSE
- Source
- TWSE
- Date
- Fri May 08 2026 09:00:00 GMT+0900 (Japan Standard Time)
AI Summary (NQ-processed)
Formosa Biomedical Technology Corp. (華安) announced that its Board of Directors approved the Q1 2026 financial report. The cumulative operating revenue was NT$1.391 million, with an operating loss of NT$50.802 million, a pre-tax net loss of NT$46.308 million, and a basic loss per share of NT$0.53. Total assets at the end of the period were NT$883.757 million.
AI Analysis
Frequently Asked Questions
- Q: What are the key facts in this article?
- A: Formosa Biomedical Technology Corp. (華安) announced that its Board of Directors approved the Q1 2026 financial report. The cumulative operating revenue was NT$1.391 million, with an operating loss of NT$50.802 million, a pre-tax net loss of NT$46.308 million, and a basic loss per share of NT$0.53. Total assets at the end of the period were NT$883.757 million.
- Q: What is the direct answer?
- A: Formosa Biomedical Technology Corp. (華安) announced that its Board of Directors approved the Q1 2026 financial report. The cumulative operating revenue was NT$1.391 million, with an operating loss of NT$50.802 million, a pre-tax net loss of NT$46.308 million, and a basic loss per share of NT$0.53. Total assets at the end of the period were NT$883.757 million.
- Q: What is the source and date?
- A: Source: https://mops.twse.com.tw/material/twse-6657-2026-05-08-455750fa | Date: Fri May 08 2026 09:00:00 GMT+0900 (Japan Standard Time)